Allogenic hematopoietic stem cell as curative treatment in myelofibrosis.
Myelofibrosis (MF) is one of the Philadelphia chromosome-negative clonal myeloproliferative disorders or chronic myeloid disorders, and it is caused by much deposit of collagen substances in bone marrow, definitely is classified as hematopoietic stem cells clonal abnormality, and related to chronic myeloproliferative disorders characterized by striking figure of extra-medullary hematopoiesis. Symptoms and signs of MF are included the variable degree of cachexia and marked extra-medullary hematopoiesis. The results of laboratory studies at presentation include anemia, leukocytosis or leucopenia, a left-ward shift in the granulocyte count, increased or decreased platelet count. Many conventional treatment modalities have been used in the MF treatment as supportive treatments. There is only one curative treatment in MF patients using allogenic hematopoietic stem cell transplantation (HSTC). The umbilical cord blood (UCB) as the source of stem cell has increased recently and gives promising results on MF.